No, Futura is currently a loss making company and therefore does not pay a dividend.
How do I transfer shares?
You will need to complete a share transfer form, which can be obtained from the Registrars. The form should be fully completed and returned to them with your share certificate to arrange transfer of ownership.
How can I confirm the number of Futura Medical shares I hold?
You will need to contact the Registrars for this information.
What is your registrar's address and how do I contact them?
Link Asset Services
34 Beckenham Road
For general enquires contact 0871 664 0300 (calls cost 12p a minute plus network extras, lines are open 9.00am-5.30pm Mon-Fri) (or +44 (0) 37 1664 0300 from outside the UK) between 09:00 and 17:30 on each business day.
My personal details have changed. What should I do?
If you have changed your name or home address you should notify the Registrars in writing. Please quote your full name, the old and new addresses, and/or provide documentary evidence (such as a copy of your marriage certificate or change of name by deed poll), as applicable. You should also enclose your share certificate for amendment.
I have lost my share certificate. How do I obtain a replacement?
You should notify the Registrars. Restriction will then be placed on the missing share certificate in case of any attempted fraud. A letter of indemnity will be sent to you to sign. Once completed and returned to the Registrars a replacement certificate can be issued. There is a charge for this service. If the missing share certificate subsequently appears, you should return it to the Registrars to be cancelled.
I am the executor for the estate of a shareholder who has died. What should I do?
Please contact the Registrar, who will be able to assist you.
Can I request a sample of MED2005?
Unfortunately, whilst MED2005 is still in development, under the current regulations, Futura Medical are not able to provide samples.
What is the difference between Eroxon, MED2002 and MED2005?
Those all refer to our topical treatment for erectile dysfunction. Eroxon® is the registered brand name under which MED2005 may be marketed, though potential distributors may choose to use other brand names.
MED2005 is the codename used by Futura for the specific final agreed formulation used in ongoing clinical trials. MED2002 was the codename used by Futura for all proprietary formulations of GTN.
How can I apply for the trial?
The recruitment for the first European Phase 3 study of MED2005 ("FM57") is now closed with headline data expected by end of 2019.
MED2005 is currently in clinical trials and is not available for purchase. If approved, MED2005 would be released as a prescription-only drug.
We believe MED2005 has the potential to eventually switch to an over the counter product that could be purchased without the need of a doctor’s prescription.
Is MED2005 available in the UK?
MED2005 is currently in clinical trials and is not available for purchase. The recruitment for the first European Phase 3 study of MED2005 ("FM57") is now closed with headline data expected by end of 2019.
What is the status of MED2005’s Intellectual Property?
MED2005's current patent protection runs until August 2028 in the USA and August 2025 in Europe. In addition EU rules grant a 10 year protection. Futura would benefit from a period of 8 years’ exclusivity during which data generated by Futura cannot be used for an MAA to support their application. In addition no generic of the product may be marketed for 10 years after the first approval.
In August 2018 Futura filed a Patent Co-operation Treaty patent application which, if successful, could extend patent protection in many countries to 2038. The PCT filing will be moving into the National filing phase in Q1 2020 in line with standard processes. This phase sets out specific, nominated countries under the Patent Co-operation Treaty which, if successful, will provide patent coverage until 2037.
Current US & EU regulations for generic topical pharmaceutical products provide further protection from competitive products as they typically require a clinical trial programme to show equivalence unlike generic oral drugs which typically only require to show bioequivalence.